Patents Assigned to Gryphon Therapeutics
  • Patent number: 7094871
    Abstract: The present invention provides methods, apparatus and kits for synthesizing assembled peptides and proteins on a solid phase with sequential ligation of three or more unprotected peptide segments using chemoselective and mild ligation chemistries in aqueous solution. Also provided are methods of monitoring solid phase sequential ligation reactions using MALDI or electrospray ionization mass spectrometry of reaction products.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: August 22, 2006
    Assignee: Gryphon Therapeutics
    Inventors: Lynne Canne, Stephen B. H. Kent, Reyna Simon
  • Patent number: 7030218
    Abstract: The present invention concerns methods and compositions for extending the technique of native chemical ligation of a wider range of peptides, polypeptides, other polymers and other molecules via an amide bond (see FIG. 1). The invention further provides methods and uses for such proteins and derivatized proteins. The invention is particularly suitable for use in the synthesis of optionally polymer-modified, synthetic bioactive proteins, and of pharmaceutical compositions that contain such proteins.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: April 18, 2006
    Assignee: Gryphon Therapeutics
    Inventors: Christie L. Hunter, Paolo Botti, James A. Bradburne, Shiah-yun Chen, Sonya Cressman, Stephen B. H. Kent, Gerd G. Kochendoerfer, Donald W. Low
  • Patent number: 7030217
    Abstract: The present invention provides methods, apparatus and kits for synthesizing assembled peptides and proteins on a solid phase with sequential ligation of three or more unprotected peptide segments using chemoselective and mild ligation chemistries in aqueous solution. Also provided are methods of monitoring solid phase sequential ligation reactions using MALDI or electrospray ionization mass spectrometry of reaction products.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: April 18, 2006
    Assignee: Gryphon Therapeutics, Inc.
    Inventors: Lynne Canne, Stephen B. H. Kent, Reyna Simon
  • Patent number: 6977292
    Abstract: The invention is directed to nucleophile-stable thioester generating compounds comprising a carboxyester thiol. The compounds have wide applicability in organic synthesis, including the generation of peptide-, polypeptide- and other polymer-thioesters. The invention is particularly useful for generating activated-thioesters from precursors that are made under conditions in which strong nucleophiles are employed, such as peptides or polypeptides made using Fmoc SPPS, as well as multi-step ligation or conjugation schemes that require (or benefit from the use of) compatible selective approaches for directing a specific ligation or conjugation reaction of interest.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: December 20, 2005
    Assignee: Gryphon Therapeutics
    Inventors: Paolo Botti, James A. Bradburne, Stephen B. H. Kent
  • Patent number: 6942852
    Abstract: N-terminally modified RANTES derivatives are disclosed. The derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis. Additionally, the compounds are useful for the treatment of HIV infection.
    Type: Grant
    Filed: October 4, 2000
    Date of Patent: September 13, 2005
    Assignee: Gryphon Therapeutics, Inc.
    Inventors: Robin E. Offord, Darren Thompson, Jill Wilken
  • Patent number: 6844161
    Abstract: Novel proteins and protein libraries are disclosed. The proteins possess one or more functional protein modules from different parent protein molecules. The proteins and protein libraries are exemplified by the preparation of cross-over chemokines that contain various combinations of peptide segments derived from RANTES, SDS-1 and vMIP-I and to vMIP-II. The proteins and libraries are extremely pure and can be provided in non-limiting high yields suitable for diagnostic and high-throughput screening assays.
    Type: Grant
    Filed: August 31, 1998
    Date of Patent: January 18, 2005
    Assignee: Gryphon Therapeutics, Inc.
    Inventors: Michael A. Siani, Jill Wilken, Reyna Simon, Stephen B. H. Kent
  • Patent number: 6673347
    Abstract: Protein and polypeptide derivatives and their salts are claimed characterized in that a protein or polypeptide is conjugated via an intermediate grouping containing at least one radical of the formula —C(R)═N— (or —N═C(R)—) or —CH(R)—NH— (or —NH—CH(R)—), wherein R is hydrogen or a hydrocarbon residue which may be substituted, with the same or a different protein or polypeptide, with a reporter group or a cytotoxic agent as well as a process for their preparation and the novel intermediates therefor.
    Type: Grant
    Filed: May 12, 1994
    Date of Patent: January 6, 2004
    Assignee: Gryphon Therapeutics
    Inventors: Robin Ewart Offord, Keith Rose
  • Patent number: 6663869
    Abstract: A homogeneous polyoxime composition is provided, in which the polyoxime molecules present comprise a first organic baseplate molecule, which is a polypeptide, wherein the baseplate molecule is linked to at least two second organic molecules, which may be the same or different from one another. In the compositions, the linkages between the baseplate and said organic molecules are oxime linkages formed by reaction of an orthogonal reactive group on each the organic molecules with a complementary orthogonal reactive group on the baseplate.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: December 16, 2003
    Assignee: Gryphon Therapeutics, Inc.
    Inventors: Keith Rose, Robin E. Offord
  • Patent number: 6552167
    Abstract: Provided are chains of precise length and methods for their preparation. These chains are formed by the reaction of a derivative of a diacid and a diamine in a stepwise manner on a support. One of the reactants contains a water soluble oligomer, preferably polyethylene glycol. These chains are then used to chemically modify target macromolecules such as biologically important polypeptides.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: April 22, 2003
    Assignee: Gryphon Therapeutics, Inc.
    Inventor: Keith Rose